About Immune Checkpoint Inhibitor
Immune checkpoint inhibitors
Immune checkpoint inhibitors enhance T cell response against malignant cells and are standard of care in many tumor types. Disinhibition of cytotoxic T cells in normal organs and inhibitrion of regulatory T cells can lead to immune-related adverse events. Immune Checkpoint Inhibitors (ICPIs) have revolutionized the field of oncology and have been shown to increase survival in many tumor types. ICPIs work by targeting molecules involved in downregulating the immune response, ultimately resulting in activation of cytotoxic T-cells and enhancing the immune system's ability to recognize and destroy neoplastic tissue.